Current practices in the management of ocular toxoplasmosis

R. E. Engstrom, G. N. Holland, R. B. Nussenblatt, Douglas Jabs

Research output: Contribution to journalArticle

Abstract

To determine current practices in the management of ocular toxoplasmosis, 72 of 85 uveitis specialists (85%) in the American Uveitis Society completed a detailed questionnaire. Questions involved the indications for beginning treatment, choice of antiparasitic/ antimicrobial agents, and experience with treatment of ocular toxoplasmosis in special situations including pregnancy, neonatal infections, and immunocompromised patients. Most of the respondents treat patients whose visual acuity had decreased to worse than 20/200, lesions located in the peripapillary, perifoveal, or maculopapillary bundle regions, and lesions associated with severe vitreous inflammation. Most would not treat patients who retained visual acuity of 20/20, lesions located in the far peripheral retina, or lesions associated with only trace to mild vitreous inflammation. Treatment of other combinations of factors remains controversial. Eight different antimicrobial drugs are used in various combinations for lesions threatening the macula or optic nerve head. Systemic corticosteroids are used by 59 of 62 respondents (95%) as part of their initial treatment regimen. The most commonly used regimens are pyrimethamine/sulfadiazine/ corticosteroids (20 of 62 [32%]) and pyrimethamine/sulfadiazine/ clindamycin/corticosteroids (17 of 62 [27%]). Adjunctive therapies (photocoagulation, cryotherapy, or vitrectomy) have been used by 20 of 60 respondents (33%). Most alter treatment during pregnancy, in newborn patients, and in patients with the acquired immunodeficiency syndrome.

Original languageEnglish (US)
Pages (from-to)601-610
Number of pages10
JournalAmerican journal of ophthalmology
Volume111
Issue number5
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Ocular Toxoplasmosis
Practice Management
Sulfadiazine
Pyrimethamine
Adrenal Cortex Hormones
Uveitis
Visual Acuity
Therapeutics
Inflammation
Antiparasitic Agents
Pregnancy
Cryotherapy
Clindamycin
Light Coagulation
Vitrectomy
Optic Disk
Immunocompromised Host
Anti-Infective Agents
Retina
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Current practices in the management of ocular toxoplasmosis. / Engstrom, R. E.; Holland, G. N.; Nussenblatt, R. B.; Jabs, Douglas.

In: American journal of ophthalmology, Vol. 111, No. 5, 01.01.1991, p. 601-610.

Research output: Contribution to journalArticle

Engstrom, R. E. ; Holland, G. N. ; Nussenblatt, R. B. ; Jabs, Douglas. / Current practices in the management of ocular toxoplasmosis. In: American journal of ophthalmology. 1991 ; Vol. 111, No. 5. pp. 601-610.
@article{9060a7796c68480abdf31292b6a5f5ca,
title = "Current practices in the management of ocular toxoplasmosis",
abstract = "To determine current practices in the management of ocular toxoplasmosis, 72 of 85 uveitis specialists (85{\%}) in the American Uveitis Society completed a detailed questionnaire. Questions involved the indications for beginning treatment, choice of antiparasitic/ antimicrobial agents, and experience with treatment of ocular toxoplasmosis in special situations including pregnancy, neonatal infections, and immunocompromised patients. Most of the respondents treat patients whose visual acuity had decreased to worse than 20/200, lesions located in the peripapillary, perifoveal, or maculopapillary bundle regions, and lesions associated with severe vitreous inflammation. Most would not treat patients who retained visual acuity of 20/20, lesions located in the far peripheral retina, or lesions associated with only trace to mild vitreous inflammation. Treatment of other combinations of factors remains controversial. Eight different antimicrobial drugs are used in various combinations for lesions threatening the macula or optic nerve head. Systemic corticosteroids are used by 59 of 62 respondents (95{\%}) as part of their initial treatment regimen. The most commonly used regimens are pyrimethamine/sulfadiazine/ corticosteroids (20 of 62 [32{\%}]) and pyrimethamine/sulfadiazine/ clindamycin/corticosteroids (17 of 62 [27{\%}]). Adjunctive therapies (photocoagulation, cryotherapy, or vitrectomy) have been used by 20 of 60 respondents (33{\%}). Most alter treatment during pregnancy, in newborn patients, and in patients with the acquired immunodeficiency syndrome.",
author = "Engstrom, {R. E.} and Holland, {G. N.} and Nussenblatt, {R. B.} and Douglas Jabs",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/S0002-9394(14)73706-7",
language = "English (US)",
volume = "111",
pages = "601--610",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Current practices in the management of ocular toxoplasmosis

AU - Engstrom, R. E.

AU - Holland, G. N.

AU - Nussenblatt, R. B.

AU - Jabs, Douglas

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To determine current practices in the management of ocular toxoplasmosis, 72 of 85 uveitis specialists (85%) in the American Uveitis Society completed a detailed questionnaire. Questions involved the indications for beginning treatment, choice of antiparasitic/ antimicrobial agents, and experience with treatment of ocular toxoplasmosis in special situations including pregnancy, neonatal infections, and immunocompromised patients. Most of the respondents treat patients whose visual acuity had decreased to worse than 20/200, lesions located in the peripapillary, perifoveal, or maculopapillary bundle regions, and lesions associated with severe vitreous inflammation. Most would not treat patients who retained visual acuity of 20/20, lesions located in the far peripheral retina, or lesions associated with only trace to mild vitreous inflammation. Treatment of other combinations of factors remains controversial. Eight different antimicrobial drugs are used in various combinations for lesions threatening the macula or optic nerve head. Systemic corticosteroids are used by 59 of 62 respondents (95%) as part of their initial treatment regimen. The most commonly used regimens are pyrimethamine/sulfadiazine/ corticosteroids (20 of 62 [32%]) and pyrimethamine/sulfadiazine/ clindamycin/corticosteroids (17 of 62 [27%]). Adjunctive therapies (photocoagulation, cryotherapy, or vitrectomy) have been used by 20 of 60 respondents (33%). Most alter treatment during pregnancy, in newborn patients, and in patients with the acquired immunodeficiency syndrome.

AB - To determine current practices in the management of ocular toxoplasmosis, 72 of 85 uveitis specialists (85%) in the American Uveitis Society completed a detailed questionnaire. Questions involved the indications for beginning treatment, choice of antiparasitic/ antimicrobial agents, and experience with treatment of ocular toxoplasmosis in special situations including pregnancy, neonatal infections, and immunocompromised patients. Most of the respondents treat patients whose visual acuity had decreased to worse than 20/200, lesions located in the peripapillary, perifoveal, or maculopapillary bundle regions, and lesions associated with severe vitreous inflammation. Most would not treat patients who retained visual acuity of 20/20, lesions located in the far peripheral retina, or lesions associated with only trace to mild vitreous inflammation. Treatment of other combinations of factors remains controversial. Eight different antimicrobial drugs are used in various combinations for lesions threatening the macula or optic nerve head. Systemic corticosteroids are used by 59 of 62 respondents (95%) as part of their initial treatment regimen. The most commonly used regimens are pyrimethamine/sulfadiazine/ corticosteroids (20 of 62 [32%]) and pyrimethamine/sulfadiazine/ clindamycin/corticosteroids (17 of 62 [27%]). Adjunctive therapies (photocoagulation, cryotherapy, or vitrectomy) have been used by 20 of 60 respondents (33%). Most alter treatment during pregnancy, in newborn patients, and in patients with the acquired immunodeficiency syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0025889999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025889999&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(14)73706-7

DO - 10.1016/S0002-9394(14)73706-7

M3 - Article

VL - 111

SP - 601

EP - 610

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -